Dunia Alarkawi
Overview
Explore the profile of Dunia Alarkawi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
148
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alarkawi D, Tran T, Chen W, March L, Blyth F, Blank R, et al.
JAMA Netw Open
. 2024 Apr;
7(4):e248491.
PMID: 38656574
Importance: A high proportion of patients who sustain a fracture have multimorbidity. However, the association of multimorbidity with postfracture adverse outcomes, such as subsequent fractures and premature mortality, has not...
2.
Bliuc D, Tran T, Alarkawi D, Chen W, Alajlouni D, Blyth F, et al.
JAMA Netw Open
. 2024 Jan;
7(1):e2352675.
PMID: 38261318
Importance: The relationship between self-reported walking limitation, a proxy of muscle function, and fracture risk has not been investigated. Objective: To examine the association between a self-reported walking limitation of...
3.
Alarkawi D, Tran T, Chen W, March L, Blyth F, Blank R, et al.
J Bone Miner Res
. 2023 Nov;
38(12):1757-1770.
PMID: 37915252
Denosumab (Dmab) is increasingly prescribed worldwide. Unlike bisphosphonates (BPs), its effect on mortality has yet to be well explored. This study examined the association between Dmab and all-cause mortality compared...
4.
Bliuc D, Tran T, Chen W, Alarkawi D, Alajlouni D, Blyth F, et al.
PLoS Med
. 2023 Jan;
20(1):e1004142.
PMID: 36649234
Background: Multimorbidity is common among fracture patients. However, its association with osteoporosis investigation and treatment to prevent future fractures is unclear. This limited knowledge impedes optimal patient care. This study...
5.
Bliuc D, Tran T, Chen W, Alarkawi D, Alajlouni D, Blyth F, et al.
J Clin Endocrinol Metab
. 2022 Nov;
108(5):e110-e119.
PMID: 36408625
Context: Bisphosphonates have been reported to be cardioprotective in some, but not all, studies. It is unknown whether denosumab (Dmab) use protects against cardiovascular events (CVEs). Objective: To determine whether...
6.
Van Meirhaeghe J, Alarkawi D, Kowalik T, Du-Moulin W, Molnar R, Adie S
ANZ J Surg
. 2021 Jul;
91(9):1908-1913.
PMID: 34268856
Background: Total hip arthroplasty (THA) provides excellent pain relief and improved function in patients with painful arthritis. The aim of this study was to identify rates and predictors of dissatisfaction...
7.
Alarkawi D, Ali M, Bliuc D, Pallares N, Tebe C, Elhussein L, et al.
J Bone Miner Res
. 2020 Jan;
35(5):894-900.
PMID: 31968134
Oral bisphosphonates (oBPs) have been associated with reduced fractures and mortality. However, their risks and benefits are unclear in patients with moderate-severe CKD. This study examined the association between oBPs...
8.
Alarkawi D, Ali M, Bliuc D, Center J, Prieto-Alhambra D
JBMR Plus
. 2018 Oct;
2(4):187-194.
PMID: 30283902
Pharmacoepidemiology is used extensively in osteoporosis research and involves the study of the use and effects of drugs in large numbers of people. Randomized controlled trials are considered the gold...
9.
Bliuc D, Tran T, Alarkawi D, Nguyen T, Eisman J, Center J
J Clin Endocrinol Metab
. 2016 Apr;
101(6):2475-83.
PMID: 27115062
Context: Hip fracture incidence has been declining and life expectancy improving. However, trends of postfracture outcomes are unknown. Objectives: The objective of the study was to compare the refracture risk...
10.
Alarkawi D, Bliuc D, Nguyen T, Eisman J, Center J
J Bone Miner Res
. 2015 Aug;
31(2):274-80.
PMID: 26241926
Fracture risk estimates are usually based on femoral neck (FN) BMD. It is unclear how to address T-score discordance, where lumbar spine (LS) T-score is lower than FN T-score. The...